Novel Devices Penetrate Migraine Headache Market

Several new device-based therapies are emerging designed to fill the treatment gap for migraine suffers who do not respond to traditional migraine therapies. These novel treatments include a headband-like device designed to stimulate the trigeminal nerve and an image-guided intranasal interventional treatment.

Migraine headaches affect at least one out of seven adults in the world according to the World Health Organization, and are one of the top 20 causes of disability. The economic burden of migraine-associated disability is significant. Migraines cost American employers an estimated $13 billion a year because of missed workdays, according to a 1999 study published in the Archives of Internal Medicine. Migraines are three times more common in women and are most disabling to people aged 35 to 45 years, although they can trouble much younger people, often starting during puberty. The most common symptoms are throbbing, pulsating pain, light and sound sensitivity, nausea, pain on one side, vision changes, blurred vision, aura, and vomiting.

Although migraines can cause substantial personal suffering, impaired quality of life, and high financial cost, these headaches are not well...

More from Clinical Trials

More from R&D